Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Drug Alcohol Depend. 2021 Aug 27;228:108985. doi: 10.1016/j.drugalcdep.2021.108985

Table 4.

Tests of precipitated withdrawal in rhesus monkeys (n=4) treated chronically with alprazolam (6 mg/kg/day).

Drug/compound Dose in mg/kg, i.v. Condition (Phase1) Combined Withdrawal Score (mean ± SEM)2
midazolam Vehicle Prior to chronic alprazolam (1) 0.0 ± 0.0
Vehicle Chronic alprazolam (3) 0.0 ± 0.0
0.1 Prior to chronic alprazolam (1) 0.0 ± 0.0
0.1 Chronic alprazolam (3) 0.0 ± 0.0
1.0 Prior to chronic alprazolam (1) 0.0 ± 0.0
1.0 Chronic alprazolam (3) 0.0 ± 0.0
zolpidem Vehicle Prior to chronic alprazolam (1) 0.0 ± 0.0
Vehicle Chronic alprazolam (3) 0.0 ± 0.0
3.0 Prior to chronic alprazolam (1) 0.0 ± 0.0
3.0 Chronic alprazolam (3) 0.0 ± 0.0
5.6 Prior to chronic alprazolam (1) 0.0 ± 0.0
5.6 Chronic alprazolam (3) 2.0 ± 2.0
HZ-166 Vehicle Prior to chronic alprazolam (1) 0.0 ± 0.0
Vehicle Chronic alprazolam (3) 0.0 ± 0.0
3.0 Prior to chronic alprazolam (1) 0.0 ± 0.0
3.0 Chronic alprazolam (3) 0.0 ± 0.0
10 Prior to chronic alprazolam (1) 0.0 ± 0.0
10 Chronic alprazolam (3) 2.5 ± 0.5
1.

For description of Phases, see Table 2.

2.

Data are number of withdrawal signs (see Table 1) recorded and averaged for 0 and 7.5 minutes after injection of test drug or compound, averaged across monkeys. No scores were significantly different from vehicle (alprazolam/no alprazolam) treatment, p<0.05.